A Study to Determine Number of Rounds of Plasma Exchange Needed to Decrease Measles Virus Antibodies for Measles Virus Cancer Therapy

Overview

About this study

The purpose of this study is to determine how many rounds of plasma exchange are required for maximal decrease in measles antibodies and how long it may last, for the successful use of measles virus cancer therapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Must be receiving a series of plasma exchange procedures for clinical reasons

 

Exclusion Criteria 

  • None

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Tobias Peikert, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions